Posted by Michael Wonder on 26 Oct 2022
Seres Therapeutics announces FDA acceptance of biologics license application for investigational microbiome therapeutic SER-109 for recurrent C. difficile infection for priority review
26 October 2022 - PDUFA target action date is 26 April 2023, with anticipated launch soon thereafter.
Seres Therapeutics today announced the US FDA has accepted for review a biologics license application for investigational oral microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection.
